LEXARIA BIOSCIENCE CORP (LEXX)

Company Profile

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. The company is headquartered in Kelowna, British Columbia and currently employs 5 full-time employees. The company went IPO on 2009-10-28. The firm's patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The company is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its primary research programs are the investigation of optimal formulations of DehydraTECH-enhanced glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drugs as well as the investigation of cannabidiol (CBD) for the reduction of hypertension leading to a cleared IND application by the United States Food and Drug Administration. The company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 46 patents granted and many patents pending worldwide.

Company Info

LEXARIA BIOSCIENCE CORP

100 - 740 Mccurdy Road

Kelowna BRITISH COLUMBIA V1X 2P7

P: 12507656424

CEO: Christopher Bunka

Employees: 5

Website: https://www.lexariabioscience.com/